{
    "nctId": "NCT01996267",
    "briefTitle": "Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2",
    "officialTitle": "Optimizing Neoadjuvant Systemic Treatment for HER2 Positive Breast Cancer - the TRAIN-2 Study",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer, HER2 Positive",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 437,
    "primaryOutcomeMeasure": "Number of patients with pathological complete response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed infiltrating breast cancer\n* Stage II or stage III disease. Nodal status must be examined by ultrasound, fine needle aspiration, sentinel node biopsy, or FDG-PET scan.\n* Overexpression and/or amplification of HER2 in an invasive component of the core biopsy, according to one of the following definitions:\n\n  \u2022\\>30% of invasive tumor cells showing strong complete circumferential membrane staining (score 3+)\n\n  \u2022HER2 gene amplification defined as \\>6 HER2 gene copies per nucleus by in situ hybridization.\n* Age \u226518\n* Eastern Cooperative Oncology Group performance status \u22641\n* Adequate bone marrow function (ANC \\>1.5 x 109/l, platelets \\>100 x 109/l)\n* Adequate hepatic function (ALAT, ASAT and bilirubin \\<2.5 times upper limit of normal)\n* Adequate renal function (creatinine clearance \\>50 ml/min)\n* LVEF \u226550% measured by echocardiography or MUGA\n* Absence of any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule\n* Absence of any medical condition that would place the patient at unusual risk.\n* Signed written informed consent\n\nExclusion Criteria:\n\n* previous radiation therapy or chemotherapy\n* other malignancy except carcinoma in situ, unless the other malignancy was treated \u22655 years ago with curative intent without the use of chemotherapy or radiation therapy.\n* current pregnancy or breastfeeding. Women of childbearing potential must use adequate contraceptive protection\n* evidence of distant metastases. Evaluation of the presence of distant metastases may include chest X-ray, liver ultrasound, isotope bone-scan, CT-scan of chest and abdomen and/or FDG-PET scan, according to local procedures.\n* evidence of bilateral infiltrating breast cancer. Evaluation of the presence of bilateral infiltrating breast cancer may include mammography, breast ultrasound and/or MRI breast.\n* concurrent anti-cancer treatment or another investigational drug.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}